Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services. Its technology and service offerings include high-throughput screening, proteomics, cell and gene-based approaches, data-driven drug discovery and the development of induced pluripotent stem cell-based disease models. The company also advances internally generated drug candidates and collaborates with partners through research alliances, licensing arrangements and co-development programs.

Founded in Hamburg in 1993, Evotec has expanded its operations through international facilities and partnerships serving customers in Europe, North America and other global markets. The company is headquartered in Hamburg, Germany, and its shares are listed in Germany, while American depositary shares trade on the Nasdaq Stock Market under the symbol EVO. Christian Wojczewski has served as Evotec’s chief executive officer since July 2024.

Key Stats

• Today's Range: $1.50 to $1.53
• 50-Day Range: $1.35 to $1.98
• 52-Week Range: $1.33 to $4.27
• Volume: 20,574 shs
• Average Volume: 113,503 shs
• Market Capitalization: $533.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 63% of companies evaluated by MarketBeat, and ranked 308th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Evotec has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Evotec has a consensus price target of $3.00, representing about 100.0% upside from its current price of $1.50.

Amount of Analyst Coverage

Evotec has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.83) to $0.04 per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evotec has recently decreased by 78.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.20

News Sentiment

Evotec has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Evotec this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Evotec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Evotec is held by insiders.

Percentage Held by Institutions

5.81% of the stock of Evotec is held by institutions.

Company Calendar

• Today: 10/25/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,553
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Evotec: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +100.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.12 million
• Net Margins: -26.20%
• Pretax Margin: -24.26%
• Return on Equity: -24.93%
• Return on Assets: -11.35%

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.33
• Quick Ratio: 2.21

Sales & Book Value

• Annual Sales: $891.97 million
• Price / Sales: 0.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 355,820,000
• Free Float: 352,261,000
• Market Cap: $533.73 million
• Optionable: Not Optionable
• Beta: 1.97